PACS Group, Inc. (NASDAQ:PACS) disclosed an insider sale this month when President and Chief Operating Officer Joshua Jergensen sold 36,335 shares of the company's common stock on March 13, 2026, a transaction reported in a Form 4 filing with the U.S. Securities and Exchange Commission.
The shares changed hands at prices between $34.28 and $34.3301, producing proceeds of approximately $1.24 million. The Form 4 reporting the sale was signed by John Mitchell, Attorney-in-Fact, and filed on March 17, 2026. After the sale, Jergensen is recorded as holding 2,667,347 shares of PACS Group, Inc.
At the time of the filing, PACS stock was trading at $35.7, following a one-year rise of 191%. The company's market capitalization stood at $5.51 billion. An InvestingPro analysis cited in the filing characterizes the stock as appearing overvalued at current levels, while noting that analysts have set price targets between $42 and $52.
Recent corporate developments for PACS Group were also detailed in the disclosures. For the fourth quarter of 2025 the company reported revenue of $1.36 billion, a 12% increase compared with the same quarter a year earlier, and net income of $59.8 million. For the full year, PACS Group reported net income of $191.5 million.
Following those results, two sell-side firms adjusted their price targets. RBC Capital raised its target to $52, citing stronger-than-expected guidance, and Truist Securities increased its target to $50, attributing the change to margin strength and adjusted EBITDA that exceeded expectations.
In addition to the financial performance and analyst revisions, PACS Group announced a board appointment. Patrick H. Conway has been named to the company's Board of Directors; Conway currently serves as CEO of Optum and previously held roles at the U.S. Centers for Medicare and Medicaid Services. The company described these items as reflecting strategic growth initiatives and positive market sentiment.
The Form 4 filing and the company's quarterly disclosures together present a snapshot of insider activity, earnings momentum, analyst reassessments and boardroom changes for PACS Group during the March 2026 reporting window.